ONCOlog and C-RAD enter into strategic agreement

Press release
November 19, 2007

ONCOlog and C-RAD enter into strategic agreement

LinkMed's portfolio company ONCOlog Medical and the medtech company C-RAD have
entered into a strategic agreement in the area of radiotherapy. Under the terms
of the agreement the companies will, in the initial stages of the agreement,
adapt their patient positioning systems to each others.

When receiving radiotherapy, patients need to be correctly positioned in order
to maximize radiation to the tumor and minimize damage to the surrounding
tissue. Currently, new advanced radiotherapy techniques, such as
intensity-modulated radiation therapy, image-guided radiation therapy (IGRT),
adaptive radiation therapy and ionizing radiation therapy, are being developed.
These new techniques make it possible to focus the radiotherapy to a defined
area, which puts further requirements on the exact positioning of the patient.

The two Swedish companies, ONCOlog Medical and C-RAD, offer technical solutions
that quickly and exactly position patients and thereafter monitor the
positioning during treatment. The aim of their strategic collaboration is, in
its initial stages, to minimize the need for CT/MR-simulation before
radiotherapy, as well as for individual fixation equipment. The collaboration
facilitates new and efficient solutions that combine ONCOlog Medical's PatLog
Load and SteroLog with C-RAD's Sentinel.

“The companies' complementing products for patient positioning ensures safer and
more efficient radiation therapy, something that is high on the agenda at
radiation clinics all over the world,” says ONCOlog Medical's CEO, Hans Dahlin.

“ONCOlog Medical's focus is to develop solutions that make radiotherapy more
effective. With this agreement, ONCOlog Medical continues to be a leader in
tomorrow's cancer therapy,” says LinkMed's CEO, Ingemar Lagerlöf.

LinkMed owns 48 percent of ONCOlog Medical. ONCOlog Medical develops, produces
and markets a number of products and system solutions for quality assurance of
radiotherapy treatment clinics for cancer.  


For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed +46 8 508 939 93



LinkMed develops new life-science companies in collaboration with innovators. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, six in drug development and biotechnology and six in medical
technology. The LinkMed share is listed on the OMX Nordic Exchange, Stockholm,
and the company's largest shareholders are FastPartner, Koncentra Holding, and
the founder Ingemar Lagerlöf. See www.linkmed.se for more information.